Candriam Luxembourg S.C.A. boosted its stake in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) by 14.0% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 24,500 shares of the biopharmaceutical company’s stock after buying an additional 3,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Intercept Pharmaceuticals were worth $2,966,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ICPT. Vanguard Group Inc. boosted its stake in Intercept Pharmaceuticals by 4.7% in the first quarter. Vanguard Group Inc. now owns 1,270,984 shares of the biopharmaceutical company’s stock valued at $143,749,000 after buying an additional 56,952 shares during the period. State Street Corp boosted its stake in Intercept Pharmaceuticals by 7.3% in the first quarter. State Street Corp now owns 805,550 shares of the biopharmaceutical company’s stock valued at $91,110,000 after buying an additional 54,523 shares during the period. Macquarie Group Ltd. boosted its stake in Intercept Pharmaceuticals by 54.2% in the first quarter. Macquarie Group Ltd. now owns 241,565 shares of the biopharmaceutical company’s stock valued at $27,321,000 after buying an additional 84,954 shares during the period. Point72 Asset Management L.P. boosted its stake in Intercept Pharmaceuticals by 13.1% in the first quarter. Point72 Asset Management L.P. now owns 220,600 shares of the biopharmaceutical company’s stock valued at $24,950,000 after buying an additional 25,500 shares during the period. Finally, Norges Bank purchased a new stake in Intercept Pharmaceuticals during the fourth quarter valued at $17,652,000. Institutional investors own 83.93% of the company’s stock.

Intercept Pharmaceuticals, Inc. (ICPT) opened at 106.26 on Wednesday. The firm’s market capitalization is $2.66 billion. The firm has a 50-day moving average price of $123.87 and a 200 day moving average price of $118.05. Intercept Pharmaceuticals, Inc. has a 52 week low of $96.63 and a 52 week high of $172.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. The firm had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The business’s quarterly revenue was up 459.6% compared to the same quarter last year. During the same period last year, the company earned ($3.14) EPS. On average, equities research analysts forecast that Intercept Pharmaceuticals, Inc. will post ($14.04) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/09/candriam-luxembourg-s-c-a-raises-stake-in-intercept-pharmaceuticals-inc-icpt.html.

A number of research firms recently commented on ICPT. Laidlaw reaffirmed a “hold” rating and issued a $119.00 price objective (up from $115.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, August 1st. BMO Capital Markets lifted their price objective on Intercept Pharmaceuticals from $218.00 to $221.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 1st. Cantor Fitzgerald set a $60.00 price objective on Intercept Pharmaceuticals and gave the stock a “sell” rating in a research note on Thursday, May 4th. BidaskClub lowered Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $231.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, May 26th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $203.67.

In other news, CEO Mark Pruzanski sold 40,000 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Monday, June 26th. The stock was sold at an average price of $130.80, for a total value of $5,232,000.00. Following the sale, the chief executive officer now directly owns 611,718 shares in the company, valued at approximately $80,012,714.40. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Daniel G. Welch sold 217 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $126.76, for a total value of $27,506.92. Following the completion of the sale, the director now owns 3,710 shares in the company, valued at $470,279.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 47,575 shares of company stock worth $6,144,469. Corporate insiders own 4.50% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.